BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36563927)

  • 1. Mutagenic potential and structural alerts of phytotoxins.
    Bassan A; Pavan M; Lo Piparo E
    Food Chem Toxicol; 2023 Mar; 173():113562. PubMed ID: 36563927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement of quantitative structure-activity relationship (QSAR) tools for predicting Ames mutagenicity: outcomes of the Ames/QSAR International Challenge Project.
    Honma M; Kitazawa A; Cayley A; Williams RV; Barber C; Hanser T; Saiakhov R; Chakravarti S; Myatt GJ; Cross KP; Benfenati E; Raitano G; Mekenyan O; Petkov P; Bossa C; Benigni R; Battistelli CL; Giuliani A; Tcheremenskaia O; DeMeo C; Norinder U; Koga H; Jose C; Jeliazkova N; Kochev N; Paskaleva V; Yang C; Daga PR; Clark RD; Rathman J
    Mutagenesis; 2019 Mar; 34(1):3-16. PubMed ID: 30357358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting the mutagenic potential of chemicals in tobacco products using
    Goel R; Valerio LG
    Toxicol Mech Methods; 2020 Nov; 30(9):672-678. PubMed ID: 32752976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transitioning to composite bacterial mutagenicity models in ICH M7 (Q)SAR analyses.
    Landry C; Kim MT; Kruhlak NL; Cross KP; Saiakhov R; Chakravarti S; Stavitskaya L
    Regul Toxicol Pharmacol; 2019 Dec; 109():104488. PubMed ID: 31586682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fragment Prioritization on a Large Mutagenicity Dataset.
    Floris M; Raitano G; Medda R; Benfenati E
    Mol Inform; 2017 Jul; 36(7):. PubMed ID: 28032691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple Instance Learning Improves Ames Mutagenicity Prediction for Problematic Molecular Species.
    Feeney SV; Lui R; Guan D; Matthews S
    Chem Res Toxicol; 2023 Aug; 36(8):1227-1237. PubMed ID: 37477941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carbamates and ICH M7 classification: Making use of expert knowledge.
    Hemingway R; Fowkes A; Williams RV
    Regul Toxicol Pharmacol; 2017 Jun; 86():392-401. PubMed ID: 28385577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extending (Q)SARs to incorporate proprietary knowledge for regulatory purposes: A case study using aromatic amine mutagenicity.
    Ahlberg E; Amberg A; Beilke LD; Bower D; Cross KP; Custer L; Ford KA; Van Gompel J; Harvey J; Honma M; Jolly R; Joossens E; Kemper RA; Kenyon M; Kruhlak N; Kuhnke L; Leavitt P; Naven R; Neilan C; Quigley DP; Shuey D; Spirkl HP; Stavitskaya L; Teasdale A; White A; Wichard J; Zwickl C; Myatt GJ
    Regul Toxicol Pharmacol; 2016 Jun; 77():1-12. PubMed ID: 26879463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A practice of expert review by read-across using QSAR Toolbox.
    Fukuchi J; Kitazawa A; Hirabayashi K; Honma M
    Mutagenesis; 2019 Mar; 34(1):49-54. PubMed ID: 30690463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extending (Q)SARs to incorporate proprietary knowledge for regulatory purposes: is aromatic N-oxide a structural alert for predicting DNA-reactive mutagenicity?
    Amberg A; Anger LT; Bercu J; Bower D; Cross KP; Custer L; Harvey JS; Hasselgren C; Honma M; Johnson C; Jolly R; Kenyon MO; Kruhlak NL; Leavitt P; Quigley DP; Miller S; Snodin D; Stavitskaya L; Teasdale A; Trejo-Martin A; White AT; Wichard J; Myatt GJ
    Mutagenesis; 2019 Mar; 34(1):67-82. PubMed ID: 30189015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potentially mutagenic impurities: analysis of structural classes and carcinogenic potencies of chemical intermediates in pharmaceutical syntheses supports alternative methods to the default TTC for calculating safe levels of impurities.
    Galloway SM; Vijayaraj Reddy M; McGettigan K; Gealy R; Bercu J
    Regul Toxicol Pharmacol; 2013 Aug; 66(3):326-35. PubMed ID: 23688841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative evaluation of 11 in silico models for the prediction of small molecule mutagenicity: role of steric hindrance and electron-withdrawing groups.
    Ford KA; Ryslik G; Chan BK; Lewin-Koh SC; Almeida D; Stokes M; Gomez SR
    Toxicol Mech Methods; 2017 Jan; 27(1):24-35. PubMed ID: 27813437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the computer programs DEREK and TOPKAT to predict bacterial mutagenicity. Deductive Estimate of Risk from Existing Knowledge. Toxicity Prediction by Komputer Assisted Technology.
    Cariello NF; Wilson JD; Britt BH; Wedd DJ; Burlinson B; Gombar V
    Mutagenesis; 2002 Jul; 17(4):321-9. PubMed ID: 12110629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A knowledge-based expert rule system for predicting mutagenicity (Ames test) of aromatic amines and azo compounds.
    Gadaleta D; Manganelli S; Manganaro A; Porta N; Benfenati E
    Toxicology; 2016 Aug; 370():20-30. PubMed ID: 27644887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Augmenting Expert Knowledge-Based Toxicity Alerts by Statistically Mined Molecular Fragments.
    Chakravarti S
    Chem Res Toxicol; 2023 Jun; 36(6):848-858. PubMed ID: 37207298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A compilation of safety impact information for extractables associated with materials used in pharmaceutical packaging, delivery, administration, and manufacturing systems.
    Jenke D; Carlson T
    PDA J Pharm Sci Technol; 2014; 68(5):407-55. PubMed ID: 25336416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutagenicity assessment strategy for pharmaceutical intermediates to aid limit setting for occupational exposure.
    Araya S; Lovsin-Barle E; Glowienke S
    Regul Toxicol Pharmacol; 2015 Nov; 73(2):515-20. PubMed ID: 26454093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integration of structure-activity relationship and artificial intelligence systems to improve in silico prediction of ames test mutagenicity.
    Mazzatorta P; Tran LA; Schilter B; Grigorov M
    J Chem Inf Model; 2007; 47(1):34-8. PubMed ID: 17238246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying the structural requirements for chromosomal aberration by incorporating molecular flexibility and metabolic activation of chemicals.
    Mekenyan O; Todorov M; Serafimova R; Stoeva S; Aptula A; Finking R; Jacob E
    Chem Res Toxicol; 2007 Dec; 20(12):1927-41. PubMed ID: 18052113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of in silico systems and expert knowledge for structure-based assessment of potentially mutagenic impurities.
    Sutter A; Amberg A; Boyer S; Brigo A; Contrera JF; Custer LL; Dobo KL; Gervais V; Glowienke S; van Gompel J; Greene N; Muster W; Nicolette J; Reddy MV; Thybaud V; Vock E; White AT; Müller L
    Regul Toxicol Pharmacol; 2013 Oct; 67(1):39-52. PubMed ID: 23669331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.